Novo Nordisk Confirms Price Adjustment for Wegovy in China

08:57 AM EST, 12/29/2025 (MT Newswires) -- Novo Nordisk (NOVO-B.CO) on Monday confirmed with MT Newswires that it is adjusting the prices of its Wegovy weight loss drug in China to "help alleviate the treatment burden for patients and improve their quality of life." The spokesperson for the Danish drugmaker made the statement in response to a same-day report from Bloomberg News that said prices will be halved in certain Chinese provinces. The news outlet also noted that Novo's patent on semaglutide will expire in March 2026 in China, which is expected to see the introduction of cheaper generics.